When an industry undergoes a radical change because of the entrance of a disruptive technology, those too cumbersome to move fast enough, too conservative to move far enough, or too complacent to believe they need to move at all may find themselves clinging to a doomed business model as the market shifts beneath them. That is, until they have been left behind by both their competition and customers.

With the pharmaceutical sector currently in the middle of such a transformative cycle, are drug developers or the firms providing them with outsourced research or manufacturing services going to find themselves similarly left behind?